Blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB)

Trial Profile

Blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB)

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Olmesartan medoxomil/azelnidipine (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms ECO
  • Most Recent Events

    • 27 Jun 2017 Status changed from recruiting to completed.
    • 08 Jan 2013 Planned end date (1 Dec 2014) added as reported by University Hospital Medical Information Network - Japan.
    • 07 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top